UBS Group’s AXS Cannabis ETF THCX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-408
Closed -$6.89K 10366
2023
Q4
$6.89K Buy
408
+289
+243% +$4.79K ﹤0.01% 7665
2023
Q3
$2.2K Buy
119
+117
+5,850% +$2.17K ﹤0.01% 7746
2023
Q2
$39 Sell
2
-193
-99% -$3.67K ﹤0.01% 8629
2023
Q1
$4.2K Sell
195
-159
-45% -$3.99K ﹤0.01% 8221
2022
Q4
$9.17K Buy
354
+132
+59% +$3.93K ﹤0.01% 8681
2022
Q3
$6K Buy
222
+159
+252% +$5.83K ﹤0.01% 9111
2022
Q2
$2K Buy
+63
New +$3.31K ﹤0.01% 9675
2022
Q1
Sell
-300
Closed -$26K 11167
2021
Q4
$26K Buy
300
+205
+216% +$22.5K ﹤0.01% 7559
2021
Q3
$12K Sell
95
-297
-76% -$43.6K ﹤0.01% 7810
2021
Q2
$67K Buy
+392
New +$68.6K ﹤0.01% 6176
2019
Q4
Sell
-69
Closed -$11K 8498
2019
Q3
$11K Buy
+69
New +$14.6K ﹤0.01% 7123

UBS Group's THCX Position: Q1 2024 in Review

UBS Group sold out of AXS Cannabis ETF (THCX) in Q1 2024, closing a stake of 408 shares — an estimated $6.89K sold.

UBS Group first reported a position in THCX in Q3 2019 and held it in 11 quarters. The position peaked at $67K in Q2 2021. 0 funds tracked by Wall St. Rank hold THCX as of Q1 2024.

  • UBS Group reported no remaining AXS Cannabis ETF position as of Q1 2024 after selling out during the quarter.
  • UBS Group sold 408 AXS Cannabis ETF shares in Q1 2024, an estimated $6.89K.
  • UBS Group first reported a position in AXS Cannabis ETF in Q3 2019 and held it in 11 quarters.
  • UBS Group's AXS Cannabis ETF position peaked at $67K in Q2 2021.
  • 0 funds tracked by Wall St. Rank held AXS Cannabis ETF as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.